PPARD and Alzheimer disease: Although no FDA-approved drugs specifically target PPARδ, a recent exploratory phase IIa clinical trial has reported that the dual PPARδ/γ agonist T3D-959 improves cognitive function in patients with mild-to-moderate AD 35, 38.